Newsletter | September 21, 2022

09.21.22 -- Why Viking Therapeutics Is Our Company To Watch

Featured Articles
Bayer Brings External Innovation Inside, With Guardrails

Can Bayer’s “arm’s-length model” for acquired companies help turn the century-and-a-half-year-old Big Pharma into a leader in gene and cell therapy, and a top 10 player in oncology?

Conducting A Drug Development Orchestra To Treat Mental Illness

Karuna Therapeutics’ late-stage drug for schizophrenia, if approved, could fund the company’s pipeline of next generation psychiatric drugs discovered through a modular constellation of CRO partners.

Companies To Watch: Viking Therapeutics

Viking Therapeutics is a broad-target contender for treating NASH in a pipeline of new drugs for metabolic and endocrine disorders.

Web-Exclusive Content
The Impact Of The Russia-Ukraine War On Clinical Trials

While the export of life-saving pharmaceuticals does not fall under sanctions for ethical reasons, all major pharma companies have vowed to stop new investments in Russia, including clinical trials. This author takes a "by the numbers" research look at the situation and analyzes where sponsor companies should reallocate clinical trials out of the affected region.

Industry Insights
Simplifying Adeno-Associated Virus Vector Production

The global demand for high-quality recombinant AAV (rAAV) manufacturing is escalating. We discuss the challenges that rAAV experts face and the best practice solutions they have employed to overcome them.

Components Of An Effective Disinfectant Prequalification Strategy

Cleaning procedures designed specifically to destroy microbial contaminants that may be present are an important component of any microbial control strategy.

The Critical Role Of CDMOs In Driving Biomanufacturing Resilience

CDMOs play a critical role in advancing the growing pipeline of novel product types, as innovators can utilize the advantages of these strategic collaborations until they are more assured of the future of their projects.

Ensuring Smooth Adaptation Of New Digital Technologies

A seamless adaptation of new digital technologies is possible if it is carefully planned and specifically tailored. Explore some of the key points related to the adaptation of digital transformation 4.0.

Pharmaceutical Distribution: Right-Sizing The Channel Strategy For Maximum Impact

The goal is to create a nimble, data-driven infrastructure that can connect the therapy to the customer base more effectively, helping to speed therapy onboarding for patients while improving visibility.

Digital Edition
September 2022 Digital Edition

Inside you will find more on:

  • Corporate Strategies
  • Leadership Lessons
  • Podcast Series Summary
  • Drug Development Tips

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable?  Read these guidelines first before submitting your idea or your article to our editorial director.